ReviewCurrent neurology and neuroscience reports2019
Pharmacological Enhancement of Stroke Recovery.
Review in Current neurology and neuroscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Targeting CX3CR1 Signaling Dynamics: A Critical Determinant in the Temporal Regulation of Post-Stroke Neurorepair.Brain sciences · 2025Review
- Astrocytes in functional recovery following central nervous system injuries.The Journal of physiology · 2024Review
- Exploring the transformative influence of neuroplasticity on stroke rehabilitation: a narrative review of current evidence.Annals of medicine and surgery (2012) · 2023Review
- Supporting Post-Stroke Language and Cognition with Pharmacotherapy: Tools for Each Phase of Care.Current neurology and neuroscience reports · 2023Review
- Cost-effective pharmacological approaches to poststroke recovery and enhanced neuroplasticity: highlighting discoveries both old and new!Annals of medicine and surgery (2012) · 2023Article
- The Implications of Microglial Regulation in Neuroplasticity-Dependent Stroke Recovery.Biomolecules · 2023Review
- Prediction of rehabilitation induced motor recovery after stroke using a multi-dimensional and multi-modal approach.Frontiers in aging neuroscience · 2023Article
- Better language through chemistry: Augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia.Handbook of clinical neurology · 2022Review
- The neuroprotective effects of pregabalin after cerebral ischemia by occlusion of the middle cerebral artery in rats.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to discuss the recent literature relating to drugs for stroke recovery and to identify some of the challenges in conducting translational research for stroke recovery. RECENT
findingsAdvances in our understanding of neural repair mechanisms in pre-clinical stroke models have provided insights into potential targets for drugs that enhance the repair/recovery process. Few drugs that act on serotonergic and dopaminergic systems have been tested in humans with mixed results. The FOCUS trial, a phase III study of early administration of fluoxetine for stroke recovery, failed to replicate the promising results of the FLAME trial, but outcome measures differed between the two trials. Another drug that has recently been shown to have potential to promote motor recovery after stroke is maraviroc, an inhibitor of C-C chemokine receptor 5 that is involved in learning and memory. Various drugs, including modulators of neurotransmitters, axonal growth inhibitor blockers, and growth factors, have been examined in preclinical and clinical studies for their ability to promote neural repair, particularly in the motor system. Neuroplasticity, broadly defined as the capacity of the brain to undergo biochemical, structural, or functional changes, is heightened early after stroke when behavioral improvements are observed. Further studies are needed to determine which of these neuroplastic processes are causal to recovery and therefore appropriate targets for drugs to promote recovery. There has also been little focus on trying to distinguish processes that promote true behavioral recovery versus those that improve task success through use of compensatory strategies. Incorporation of sensitive and detailed outcome measures that assess movement quality as well as task success in both preclinical and clinical studies are needed to further elucidate appropriate drug targets and improve the translation of preclinical findings into successful clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.